News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Orion Pharma’s Mixed Results; Abbott Laboratories Shares Drop After Study Of Simdax Disappoints
November 15, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Nov. 15 (Bloomberg) -- Shares of Orion Oyj, the Nordic region's third-largest drugmaker, dropped as much as 14 percent after researchers said the Simdax heart failure treatment caused some complications and didn't lower death rates.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
Abbott Laboratories
MORE ON THIS TOPIC
Podcast
Modernagate Fallout, Disc’s Rejection, Compass’ Psilocybin Data, CDC’s Lost Leaders
February 18, 2026
·
1 min read
·
Heather McKenzie
Rare disease
Disc’s Regulatory Comeback Plan for Rejected Drug Relies on Old FDA Leadership
February 17, 2026
·
3 min read
·
Annalee Armstrong
Vaccines
Does Vaxart Hold the Key to the Elusive Norovirus Vaccine?
February 17, 2026
·
3 min read
·
Dan Samorodnitsky
Immunology and inflammation
Ocular’s Hydrogel Beats Regeneron’s Eylea in Wet AMD Study, Plots Path to FDA
February 17, 2026
·
2 min read
·
Tristan Manalac